In the final results from the three-year SURMOUNT-1 trial, tirzepatide lowered the risk of progression to Type 2 diabetes by 94% versus placebo in adult prediabetic patients who were obese or overweight
Other emerging non-weight loss benefits of semaglutide currently being researched include: Polycystic Ovary Syndrome (PCOS): By improving insulin resistance, semaglutide may help manage the symptoms of PCOS, a hormonal disorder that affects many women of reproductive age
Balancing Semaglutide Dosing and Eating Windows If you are using semaglutide and practicing intermittent fasting, it is essential to coordinate your eating windows and medication timing
Researchers have found that the amount of leaked fluid after subcutaneous injections of insulin is not enough to reduce the doses effectiveness
Initial Bioimpedance Spectroscopy Results: Weight: 234 lbs Body Fat: 45.7% BMI: 33.4 Body Fat Mass: 109 lbs Lean Body Mass: 130 lbs Skeletal Muscle Mass: 71 lbs ECW/TBW (Extracellular Water/Total Body Water): 0.401 in both legs Rapid Improvements with GLP-1 Within just three weeks on Tirzepatide, JH noticed significant changes
The hypotriglyceridemic effect of LC may be due to its effect on lipase hyperactivity and antioxidant efficacy, which could lower serum lipid levels
